Back to search results

Nimodipine Variability in SAH

This study is looking at nimodipine, a medication given to people who have had a subarachnoid hemorrhage (SAH). SAH is bleeding in the brain from a ruptured aneurysm (a weak, bulging blood vessel). Nimodipine is the only medication proven to help patients after SAH. Researchers want to understand why the amount of nimodipine in a person's blood can vary, even though everyone gets the same dose. They will measure your recovery 90 days after you are admitted to the hospital. You may be able to join if you are 18-85 years old, have been diagnosed with aneurysmal SAH, are treated with nimodipine, and have an intravascular catheter (a thin tube placed in a blood vessel). This is an observational study, meaning researchers will collect information without giving you a new treatment. The study plans to include 500 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information without giving you a new treatment. It plans to include 500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your recovery will be measured 90 days after hospital admission.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07065903

Nimodipine Variability in SAH

Recruiting
Not specifiedAges 18–85Observational
University of Alberta
~500 participants
Updated 2026-02-09 on ClinicalTrials.gov

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
modified Rankin Scale (mRS) score
Measured over 90 days from hospital admission

Conditions

Subarachnoid Aneurysm Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal

Explore related trials

Subarachnoid Hemorrhage

Where it's being run

3 sites across 3 states
Virginia1
Alberta1
Ontario1

Who to contact

Sherif H Mahmoud, BSc (Pharm), MSc, PhD, FNCS
[email protected]
780.492.5364
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-85 years
Diagnosis of aneurysmal SAH
Provision of informed consent
Treated with nimodipine
Presence of intravascular catheter at the time of sampling

Exclusion

Anticipated hospital length of stay \<48 hours
Non-aneurysmal SAH
Not treated with nimodipine
Incarceration
Delayed presentation to the hospital (\>96 h from SAH onset)

What this trial measures

  • modified Rankin Scale (mRS) score90 days from hospital admission

    The mRS is a measure of disability ranging from 0 (no symptoms) to 6 (death) and is the recommended functional outcome scale in studies involving SAH patients.